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Abstract 
Redox Regulation of DNA Repair: 
Implications for Human Health 
and Cancer Therapeutic Development 
Meihua Luo~ Hongzhen He,2 Mark R. Kel ley~-3 and Millie M. Georgiadis2.4 
Red.ox reactions are known to regulate many important cellular processes. In this revievv, v.re focus on the role of 
redox regulation in DNA repair both in direct regulation of specific DNA repair proteins as well as indirect 
transcriptional regulation. A key player in the redox regulation of DNA repair is the base excision repair enzyme 
apurinic/apyrimidinic endonuclease 1 (APEl) in its role as a redox factor. APEl is reduced by the general redox 
factor thioredoxin, and in turn reduces several important transcription factors that regulate expression of DNA 
repair proteins. Finally, we consider the potential for chemotherapeutic development through the modulation of 
APEl's redox activity and its impact on DNA repair. Antioxid. Redox Signal. 12, 1247-1269. 
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I. Introduction 
ALTHOUGH THE IMPORTANCE of DNA-repair pathways in protecting the genome from damage caused by endog-
enous and exogenous DNA-damaging agents (40, 44, 60) has 
long been recognized, the role of redox regulation in these 
pathways is a relatively recent discovery. In writing this re-
vie'~', vve attempted to guide the reader through general as 
well as specific aspects of DNA repair and redox regulation, 
focusing u ltimately on the connection beh-veen the h-vo. We 
begin vvith an overview of DNA-repair pathways leading to a 
more in-depth discussion of one specific DNA-repair path-
way, the base excision repair (BER) pathway. We focus on the 
BER pathway, which is responsible for the repair of DNA 
damage caused by oxidation, alkylation, and ionizing radia-
tion, and specifically on apurinic/ apyrimidinic endonuclease 1 
(APEl ), the only DNA-repair protein currently known to serve 
a dual role as a repair enzyme and a redox factor. In its role as a 
redox factor, APEl modifies downstream trai1scription factors 
such as AP-1, NF-KB, CREB, p53, and others, and thereby in-
directly alters the activity of other DNA-repair pathways. To 
p ut the redox activity of APEl in perspective, we provide an 
overvievv of general redox systems as well as an in-depth 
discussion of the redox activity of APEl. Finally, in consider-
ing the impact of redox regulation of DNA repair to human 
health, we discuss the modulation of the redox activity of 
APEl by small molecules and the potential for chemothera-
peutic development targeting redox regulation of DNA repair. 
II. DNA-Repair Pathways 
The genome of eukaryotic cells is constantly under attack 
from both endogenous and exogenous DNA-damaging 
agents. DNA damage resulting from endogenous agents in-
cludes oxidation by reactive oxygen species (ROS) generated 
from normal 1netabolic processes, alkylation by agents such as 
5-adenosylmethionine, adduct fonnation resulting from at-
tack by reactive carbonyl species fonned during lipid perox-
idation, hydrolytic depurination leading to the formation of 
abasic sites, or deamination of bases, primarily cytidine, and 
to a lesser extent, adenine (44). Exogenous agents include 
envirorunental insults (chemicals, carcinogens, UV light), 
che1notherapeutic agents, and radiation dan1age (40, 60). 
Failure to repair DNA damage in both postmitotic and mitotic 
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FIG. 1. Schematic overview of DNA-repair pathway. Several DNA-repair pathways are involved in maintaining cell 
genomic stability; these include direct repair (DR), base-excision repair (BER), nucleotide-excision repair (NER), mismatch 
repair (MMI{), homologous recombination (HR), and nonhomologous end joining (NHEJ). More than 150 proteins are 
involved. Only selected genes of each path\·vay ai·e shown here. [Adapted from Fishel et al. (57).) 
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cells can result in apoptosis or accumulation of mutations and 
even cell-cycle arrest (58, 106). For example, the DN~-dam~ge 
response in 1nitotic cells results in cell-eye!~ ar_rest mvolvmg 
the major cell-cycle machinery. Tn postm1totic cells, DNA 
d amage may result in cell-cycle activation and subsequent 
arrest, leading to deleterious events in this cell population as 
well (110, 160). However, we have evolved a series of DNA-
repair pathways to correct the damage, incl_uding ~~ect repa~ 
(DR), base-excision repair (BER), nucleot1de-exas1on_ re~arr 
(NER), mismatch repair (MMR), homologous recomb1n~tion 
(HR), and nonhomologous end joining (NHEJ) (85, 86) (Fig.~). 
The number of DNA-repair proteins and factors involved 111 
the cellular response to DNA damage keeps growing as 
m ore and more information is obtained, not only on the DNA 
repair enzymes involved in each path,.vay, but a lso on the 
regulatory networks that are induced by persis~ence o_f DNA 
darnage in the cell (182). Dis tinct DNA damage IS reparred by 
the different pathways and mechanisms. Overlap and inte_r-
action between the various pathways and some overlap In 
mechanisn1s occur. For example, 0 6-n1ethylguanine can 
be removed directly by 0 6-m ethylguanine-DNA methyl-
transferase (MGMT or AGl) in DR, but if this pathway is not 
successful, the 0 6mG mispairs and is recognized by the MMR 
pathway (59). Similarly, oxidative DNA dam~ge is ~epaired 
mainly by BER, but som e repair by NER also lS possible (53). 
Single-sh·and DNA breaks (SSBs) unrepaired by BER lead to 
d ouble-strand breaks (DSBs), which may be repaired by HR, 
and HR can also repair DNA DSBs that NHEJ pathways fa il to 
process (49). Interaction of different DNA-repair pathways 
and mechanisms provides the most efficient defense for the 
cell genome, whereas reduced repair capacity ca:' lead . to 
genomic instability. A number of diseases are as~oc1ated with 
defects in DNA repair, including xeroderma p1gmentosum , 
Cockayne syndro1ne, tridothiodys trophy, Werner syndrome, 
and Bloom syndrome (118, 162). The reader is directed to 
recent comprehensive reviews for more specific information 
on each DNA-repair pathway (47, 111, 144, 145, 150, 157, 174). 
For updated information on the individual repair proteU:-S, the 
following link m ay prove i.1seful: http://W\.vw_.cga l.1cnet/ 
DNA_Repair_Genes.html (182). What follows is an over-
view of ONA-repair pathways necessary to provide a con-
text for understanding the role of redox regulation in DNA 
repair. 
A. Mammalian direct repair: d'-alkylguanine-DNA 
methyltransferase or d'-methylguanine-DNA 
methyltransferase 
This type of repair in mammals is tern1ed direct reversal 
because the damaged base is repaired through removal of the 
alteration to the base instead of ren1oval of the d a1naged base. 
It is i.mique in this sense and probably is the most efficient 
mechanism of repair (105). The protein that carries out this 
reaction, the AGT protein, removes alkyl groups through di-
rect transfer from the 0 6 position of guanine and to a lesser 
extent from the 0 4 position from thymine to the protein, 
leaving a guanine or thymine in DNA and inac~va ted protein. 
This L5 a stoichiometric reaction, as one protem removes one 
alkyl group and is then degraded. It is essential to repair 
0 6-meG adducts, as they cause errors by mispairing with 
thymine during replication, leading to G:C to A:T transitions 
or a strand break. 
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B. Base-excision repair 
BER is responsible for the repair of DNA damage arising 
fro1n alkylation, d eamination, or oxidation of bases (8, 40, 50). 
Alkylation of bases arises from exposi.rre to either endogenous 
agents such as S-adenosylmethionine or exogen~us agents, 
including environmental and chemotherapeu tic agents, 
w hereas deamination of cytidines and adenines occurs spon-
taneously. Oxidative damage can result from ROS generated 
by normal cellular processes, in addition to envirorunental or 
chemotherapeutic agents. BER is initiated by the removal of 
the damaged base through enzymes called DNA glycosylases, 
which specifically recognize several different types of base 
damage. Glycosylases are of two types, monofunctional and 
bifunctionaL Monofunctional glycosylases (e.g., N-methyl 
purine DNA glycosylase (MPG or AAG)] excise the d~a~ed 
base to generate an apurinic/ apyrimidinic (AP) or abas1c site, 
which is acted on by the multifunctional AP endonuclease, 
APEl. Bi functional glycosylases such as human 8-oxoguanine 
ONA glycosylase (hOGGl), human endonuclease VIII- like 
DNA glycosylase (NEILl-3), and E. coli endonucl~ase III 
(NTH) glycosylase have an additional A!' lyase function (~6, 
43) that excises the damaged base and rucks the phosphod1e-
s ter backbone 3' to the AP site. The resulting AP site is pro-
cessed by APE1, which hydrolyzes the phosphodiester 
backbone immediately 5' to the AP site, creating 3' OH and 5' 
deoxyribose phosphate (5' dRP) te rmini. At this s tage, repair 
can proceed by two pathways: the short-patch BEl~ (SP-BEl~) 
pathway and the long-patch BER (LP-BER)_ p~th.way. APEl is 
responsible for 95°/o of the endonuclease act1v1ty 1n the cell and 
is a critical part of both the short-patch and the long-patch BER 
pathway (45, 46). SP-BER repairs normal AP sites. DNA 
polymerase f3 (pol /3) removes the 5' dRP moiety by its dRPase 
activity and u ses the 3' OH terminus to insert the correct b~s~. 
The nick is ligated by DNA ligase ill/ XRCCl, and reparr lS 
completed. The LP-BER pathway preferentially repairs oxi-
dized and reduced AP si tes and is a minor branch of the BER 
pathway. A segment or fl ap of three to eight n_uc leo~des Sttr-
rounding the AP site is displaced, followed by insertion of t~e 
correct nucleotides by DNA polymerase b, s, or {3, along with 
proliferating cell nuclear antigen (PCNA) and replication 
factor-C (RF-C). After resynthesis, flap endonuclease 1 (FENl) 
removes the displaced s trand, and DNA ligase T, or the DNA 
ligase ill/ XRCCl complex ligates the nick. APEl i..r; the only AP 
endonuclease that performs these functions in the BER, and as 
such, is a key player in the BER process. APEl also coordinates 
recruitment of other DNA-repair proteins involved in BER 
throu gh a comp lex network of direct pr~tei~-protein inter~c­
tions and indirect interactions, as shown in Fig. 2. N o effective 
backup to APEl activity exists in the cell'. as is disc~. in 
more detail later, including its other tna1or redox-s1gnaling 
function. 
C. Nucleotide-excision repair 
The NER pathway is responsible for repairing large ad-
ducts such as ultraviolet-light- induced cyclobutane pyrimi-
d ine dimers, adducts induced by polycyclic aromatic 
hydrocarbons, and other bulky DNA lesions _induced. by 
cross-linking agents and base-damaging che1mca~ carci_no-
gens. Numerous proteins are required to co~plet~ ~ER: More 
than 25 proteins/ complexes have been identified m e~­
karyotic cells; these can be further divided into two main 
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FIG. 2. Network of protein- protein interactions involving APEl (adapted from ref. 51). APEl plays an essential role in 
BER through its enzymatic activity as well as its role in coordinating interactions, either directly (solid lines) or indirectly 
(dashed lines), with a large nLnnber of other proteins involved in BER. Proteins highlighted are central components with APEl, 
apurinic/apyrimidinic endonudease, in the middle. Those proteins in the first column are DNA glycosylases; the remaining 
proteins include PCNA, an accessory protein; polymerases, pol P and pol <5; ligase 1, LIGl; and the flap endonuclease, FENl. 
subpathways; global genome repair (GGI~) and transcription-
coupled repair (TCR), depending on the complexes that ini-
tiate repair (8, 63). TCR is initiated ""hen RNA polymerase II 
(RNA Pol TI) stalls at sites of DNA damage. TCR-specific 
factors, including the Cockayne syndrome proteins, CSA and 
CSB, are recruited at the site of transcription arrest, follo;ved 
by removal of the lesion by NER enzymes. In contrast, the 
heterodirner XPC/ HR23B appears to be the major damage-
recognition factor in hun1an cells. The UV-DNA damage-
binding protein UV-DDB is additionally required for NER of 
UV-induced cyclobutane pyrimidine d imers. After recogni-
tion, both TCR and GGR use the same proteins to repair the 
damaged DNA. The transcription-factor ITH (TFIIH) complex 
is recruited to the site of DNA damage, including its compo-
nent heli.cases, XPB and XPD (xerodem1a p igmentosum 
complementary group B and D proteins) that unwind the 
DNA strand on either side of the DNA damage. XPA and RPA 
(replication protein A) stabilize the exposed single-strand 
DNA followed by cleavage of the 27- to 30-nucleotide frag-
ment 3' and 5' of the lesion by endonucleases XPG and 
ERCCl/XPFl/XPF. The resulting gap is filled in by the DNA 
polymerases{> ore, along with PCNA, RPA, and replication 
factor C (RFC) by using the undamaged strand as a template. 
D. Mismatch repair 
In a broad definition, MMR is responsible for the recogni-
tion and repair of single mismatches or misaligned short 
nucleotide repeats. Mismatches can be endogenously caused 
by spontaneous deamination of 5-methylcytosine to thy1nine, 
resulting in a guanine-to-thyinine mismatch, damage to the 
cellular nucleotide pool, cytosine deamination to uracil, 
resulting in a guanine-to-uracil mismatch, or incorrect incor-
poration by DNA polymerase. A complex of MSH2 and MSH6 
recognizes the mismatd1 and initiates the pathway. Various 
conwi.nations of MSH2 and either MSH3 or MSH6 are fom1ed, 
which specify the type of mismatch recognized. For exam-
ple, when MSH2 is paired with MSH6, it recognizes both 
insertion-deletion mispairs and single-base mismatches, 
whereas \·vhen it is paired with MSH3, the complex recog-
nizes insertion-deletion mispairs. After recognition, MSH 
proteins recruit MLHl and its binding partners, post-meiotic-
segregation increased-I protein (PMSl) and PMS2. An 
exonuclease removes the DNA lesion, a DNA polymerase 
synthesizes a new strand, and finally, a DNA ligase completes 
the repair. This has been previously reviewed (104, 126). 
E. Nonhomologous DNA end-joining 
and homologous recombination 
NHEJ is the main repair pathway for DSBs in mamma-
lian cellc;. DNA DSBs may be caused by ionizing radiation (IR), 
chemotherapeutic drugs, cleavage during V (D) J-recombi-
nation, meiotic recombi11ation, or the collapse of replication 
forks. DSBs are the most severe fo1m of DNA dan1age and 
endanger genomic stability by coordinating deletion or 
translocation or both of chromosomal DNA. Proteins in-
duding, but not limited to, Ku 70, Ku 80, DNA ligase IV, and 
XRCC4 are part of the NHEJ-repair pathway. The Ku proteins 
bind to the ends of broken DNA and, as a complex with DNA-
PKs (DNA-dependent kinase catalytic sub\.nut), interact '~1ith 
DNA li.gase IV ai1d XRCC4 to repair DNA through the NHEJ 
pathway. DNA ligase IV and XRCC4 function in a complex to 
ligate the nick and to complete repair (34). Discovery of neV\' 
proteins involved in NHEJ includes Metnase or SETMAR 
(117), which has been shown to interact with DNA ligase lV 
and to enhance the efficiency and accuracy of NHEJ (92). 
Homologous recombination (HR) also is i11volved in re-
pairing DNA DSBs. HR is initiated through the DSB recog-
nition by ATM (ataxia telangiectasia-mutated protein), which 
phosphorylates multiple downstream proteins. DSBs are 
processed by the MRN complex (Mrell/Rad50/Nbsl) nu-
clease activity to yield single-sh·and DNA (ssDNA). ATM-
activated BRCAl attracts BRCA2 and RADSl to bind to the 
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FIG. 3. Reduction of oxidized proteins by TRX. Thioredoxin (TRX) reduces oxidized proteins containing a disulfide 
through the formation of a mixed disulfide intermediate involving nucleophilic attack by Cys 32 of the CXXC motif. The 
mixed disulfide is then resolved by Cys 35, resulting in the formation of a disulfide bond in thioredoxin. Ribbon renderings are 
shown for the reduced (PDB identifier, lEl{T) and oxidized thioredoxin (PDB identifier, lEl{U) along with the Cys residues of 
the CXXC motif in black-stick renderings. 
ssDNA ends, allowing the RAD52/ RAD54 complex to join 
and fom1 larger co1nplexes with BLM and WRN proteins. 
These large protein complexes at the strand break direct 
pairing of the p rocessed DNA with a homologous region on 
the sister chromatid and initiate strand exchange. This was 
previously reviewed in detail (167). 
Ill. General Redox Systems 
In living systems, two systems are primarily responsible for 
general reduction-oxidation (redox) regulation, the thior-
edoxin (TRX) and glutaredoxin/ glutathione (GRX/ GSH) 
systems. They maintain the redox cellular homeostasis as '~'ell 
as redox regulate several cellular processes through a thiol-
redox mechanic;m (91, 142). Thiol-based redox mechanisms 
rely on the special properties of Cys residues, which can adopt 
10 different sulfur oxidation states from +6 to -2 (the fully 
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FIG. 4. Thioredoxin reductase/ thioredoxin (TR/ TRX) 
redox cascade. Thioredoxin is reduced by thioredoxin 
reductase in a somewhat more-complex mechanism involv-
ing the formation of a selenylsulfide and subsequent reduc-
tion by a pair of Cys residues within another subunit of TR. 
Electron-transfer reactions involving the F ADH2, a cofactor 
of Tl{, and NADPH are required to regenerate TR. [Adapted 
fro1n Jacob et al. (100).] 
reduced state) (69, 100). Cys can exist in a number of different 
forms in vivo, including cysteinyl radical, sulfenic acid, sulfi-
nic acid, sulfonic acid, cystine, and others [see Jacob et al. (100) 
for a recent review of sulfur chen1istry associated with Cys]. 
Of the types of reactions involving Cys residues, the thiol/ 
disulfide exchange reaction Le; of relevance to our dLc;cussion of 
general redox systems [reviewed in (69)]. In thiol/ disulfide-
exchange reactions, an oxidized protein, including a disulfide 
bond, is recognized by a reduced protein such as TRX or 
GRX/ GSH and is then reduced through the formation of an 
intermediate mixed disulfide bond (Fig. 3). Cys acts as a 
nucleophile in this type of reaction (69, 100). Interestingly, 
Tl{)( and GRX/ GSH are reduced by thioredoxin reductase 
and glutathione reductase, respectively, in a reaction involv-
ing both thiol/ disulfide exchange and electron-transfer reac-
tions requiring cofactors such as FADH2 and NADPH (Fig. 4) 
(69, 100) 
A. The thioredoxin system 
Components of the thioredoxin system include thioredoxin 
(TRX), NADPH, and thioredoxin reductase (TR) (90, 100). 
Thioredoxins (TRXs) comprise a large family of structurally 
conserved proteins that serve as general protein disulfide 
oxidoreductases and can reduce disulfide bonds in a va1iety 
of proteins through a thiol/ disulfide exchange mechanism 
(143). Oxidized thioredoxin is then reduced by thioredoxin 
reductase, a flavoprotein containing a selenocysteine, in a 
reaction involving NADPH. 
Thioredoxins (Tl{)(s) share a similar active-site motif Cys-
X-X-Cys and a common structural motif, kno,vn as the TRX 
fold (91, 120, 153), 'vhich consists of a four-stranded /J-sheet 
surrounded by three a-helices (Fig. 4). The active-site motif is 
located on the loop connecting /J-sheet 1 and a-helix 1. The N-
terminal Cys residue in the active site is surface exposed and 
has a lo,.v pK. value; for example, Cys32 in human TRX has 
an estimated pK. of 6.3 (61), whereas the C- terminal Cys is 
buried in the molecule and has a much higher pK., value. It has 
been proposed that the low pK., value of the N-terminal Cys 
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arises from the partial positive charge from the dipole 
mon1ent associated with et.-helix 2 (88), or alternatively, may 
be due to its hydrogen bond to the C-term.inal Cys (181). The 
nucleophilicity of the thiolate group of the Cys is increased by 
the low pK •. The proposed reaction mechanic;m of disulfide 
reduction by thioredoxin is as follows: the N-term.inal cyste-
ine thiolate of TRX acts as a nucleophile and attacks the target 
disulfide, resulting in a transient mixed disulfide inte1me-
diate, vvhich is, in turn, reduced by the C-te1minal active-
site Cys residue, generating a dithiol in the target protein 
and a disulfide in thioredoxin (91, 108, 120) (Fig. 3). The 
resulting disulfide in the active site of TRX can be reduced by 
Tl~ with electrons from NADPH, completing the catalytic 
cycle. 
The mechanism by ,.vhich TR reduces TRX back to the di-
thiol involves the fonnation of a selenylsulfide in the active 
site of TR (100), as shown in Fig. 4. A second redox active site 
located in the other subunit of the dimeric TI~ contains two 
thiols that reduce the selenylsulfide back to a thiol and selenol, 
with the resultant formation of a disulfide bond. This dis-
ul fide is reduced by electron transfer from FADH21 and the 
resulting FAD is then reduced by electron transfer from 
NADPH (100). 
B. The glutaredoxin/ glutathione system 
The glutaredoxin system is composed of NADPH, the 
flavoprotein glutathione reductase, g lutathione, and glutar-
edoxin (54, 90, 121). This system also works through a cas-
cade of disulfide oxidation and reduction. Glutaredoxins 
(GRXs) are small redox enzymes of ~ 100 amino acid resi-
dues, which use gluta thione as a cofactor. Structurally glu-
taredoxins are very similar to thioredoxins, retaining the 
same fold and active sites. However, the active site of GRXs 
includes Cys-X-X-Cys or Cys-X-X-Ser. By using a similar 
reactive mechanism, GRXs catalyze the reversible reduc-
tion of substra te protein disulfides, resulting in oxidation of 
the GRXs (Fig. 5). Oxidized GRXs are reduced none-
nzymatically by glutathione (glutamyl-cysteinyl-gly-
cine,GSH), and then the oxidized glutathionine disulfide 
(GSSG) is reduced by glutathione reductase at the expense of 
NADPH (121). 
C. Roles of general redox systems 
Tlu·ough a thiol/ disulfide exchange mechanism, thior-
edoxin and gluta redoxin systems maintain a reducing intra-
H. 
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cellular redox state, which is an important metabolic variable, 
influencing many aspects of cell function, like growth, apo-
ptosis, and reductive biosynthesis. Tn addi tion, by redox sig-
naling, they control the activat ion of a number of transcrip tion 
factors and hence regulate a broad range of cellular functions 
(11, 153, 192). The two redox systems physiologically play 
many roles in different organisms and, conversely, are also 
pathophysiologic factors for a va1iety of hun1an diseases, in-
cluding cancer, viral disease, Alzheimer's disease, and others 
(7, 12, 33, 154), and hence serve as vital drug targets for cancer 
therapy and other disease treatments (20, 39, 122, 123, 141). 
Although the thioredoxin system and glutaredoxin syste1n 
share a number of ftu1ctions, they are not just simple duplicate 
systems; TRX and GRX act on different substrates (54, 121). 
TRX but not GRX, for example, has been implicated in the 
reduction of APE1 (6, 83, 94, 170). 
The remainder of our discussion on redox factors focuses 
on APE1, which is the only DNA-repair protein kno,-vn also 
to have a role in redox regulation affecting the expression of a 
number of other DNA-repair proteins. 
IV. The Redox Activity of APE1 
In a search to identify the nuclear factor responsible for 
reducing the transcription factor AP-1., a factor termed redox 
effector factor 1, Ref-1, '~'as identified (184, 187). Since this 
initial dic;covery, APEl (Ref-1) has been reported to reduce a 
number of other ilnportant transcription factors, includil1g 
NF-KB, HIF-la, p53, PAX, and others (35, 48, 83, 84, 112, 169, 
175) (Fig. 6). And, as discussed below, the redox activity of 
APEl plays an important ro le in regulating the expression of a 
large number of DNA-repair proteins. 
A. Evolution of the redox function of APE1 
Although APE1 is reported to have distinct redox and re-
pair domains (186) located "vithin the N- and C-term.inal re-
gions of the protein, respectively, these functional domains do 
not correspond to independently folded domains within the 
proteil1 (i.e., structural domains). Furthermore, the repair and 
redox activi ties do not appear to be coordinated within hu-
man APEl, and '"'hereas the AP endonuclease activi ty of 
APEl is conserved from bacteria to humans, the redox func-
tion is unique to mammals. Tl1us, as shown in Fig. 7, APEl 
and E. coli exonuclease lil, the major AP endonuclease found 
within E.coli, are closely related in terms of shucture (r.m.s.d., 
1.5 A), retaining not only the sa1ne overall fold and topology 
H 
H 
rot 
FIG. S. Reduction of oxidized p roteins 
by glutaredoxin/ glutathione (GRX/ 
GSH ). Through a mechanism similar to 
that used by TRX, GRX also forms a 
mixed-disulfide intennediate '"'ith an 
oxidized protein. This disulfide is re-
solved through involvement of a second 
Cys residue of the CXXC motif in GRX, 
resulting in reduction of the protein and 
formation of a disulfide bond in GRX. 
GSH directly reduces GRX again through 
a disulfide-exchange mechanism and is 
itself reduced by glutathione reductase. 
[Adapted from Lillig et al. (121).] 
REDOX REGULATION OF DNA REPAIR 
(reduced) 
APE1/Ref-1 
(oxidized) 
Redox Regulation 
APE1/Ref-1 
redox activity inhibited 
(oxidized) 
~ 
(reduced) 
l 
AP-1 
p53 
NF kB 
HLF 
HIF-1cx 
CREB 
ATF 
Egr-1 
NF-Y 
PAX 
Redox control of 
Transcription factors 
l 
Gene expression 
changes 
Binding of 
APE1 to the 
AP site 
blocked. 
CRT0044876 
DNA Repair 
_ ._G-A-A-T-C -
-~C-T-~A-G-
! 
Glycosylase (Ogg1 , Nth1) 
-....... -r-c-
-~o-r-r-A-~ ----
Methoxyamine 
_ T-G * "A-:::- ~...!.( .:...M.:...X:-.) __. 
-A-C-T-T-~-
APE1/Ref-1 ---• 
repair activity 
inhibited 
- A-C-T-T-A-G-
ONA Ligase 
- T-C r#&i- C-
- P-{;-T-T-A-G-
1253 
FIG. 6. APEl has dual roles in redox and DNA repair. APEl possesses two major functions: redox regulatory / signaling 
and DNA repair. Tirrough its redox function, APEl regulates gene expression by modifying the redox status of some tran-
scription factors involved in variety of cancer processes. S1nall molecules that block APEl redox function are shown in ovals. In 
addition to its redox function, APEl plays a critical role in the BER DNA-repair pathway as an AP endonuclease, which 
processes the AP sites. Blocking AP sites by using methoxyamine (MX) or APEl or both directly by using APEl-specific 
inhibitors such as CRT0044876 may decrease DNA repair and lead to tumor-cell death. [Adapted from Luo et al. (128).) 
but also very similar endonudease active sites (Fig. 8). The 
sequence identity between APEl and exonuclease III is 27.7%. 
The most obvious structural difference between human APEl 
and exonuclease III is an additional 62 N-terminal residues 
found only in APEl (Fig. 7). Within this N-terminal region of 
APEl is a nuclear localization sequence. However, addition of 
N-tenninal residues alone does not confer redox activity; 
zebra fish APE includes a similar N-terminal addition (Fig. 9) 
but lacks redox activity (68). 
So the question then becomes, what is required for the re-
dox activity of human APEl (hAPEl)? This continues to be a 
source of controversy in the literature. Of the seven Cys res-
idues present in hAPEl, Cys 65 1.vas identified as the critical 
residue required for redox activity tlu·ough analysis of single 
Cys-to-Ala substitutions within APEl (see Fig. 10) (178). In-
vestigation of the role of Cys residues \.vithin APEl was based 
on the finding that a Cys residue within the DNA-binding 
domain of the transcription factor c-Jun was subject to oxi-
dation, leading to loss of DNA bindings and \.vas reduced by 
APEl (2, 184, 187). Subsequently, the crystal structure of 
human APEl was reported (70), revealing that Cys 65, a res-
idue unique to mammalian sequences, is a buried residue 
located on the first fJ strand in the fold, which is part of a fJ 
sheet in the core of the protein (Fig. 10). The residue equiva-
lent to the hAPEl Cys 65 in exonuclease III, based on struc-
tural aligrunent, is Val 4, whereas that in zebrafish APEl 
(zApe) is Thr 58 (68). Conservation of Cys residues beh.veen 
------N-terminal region of hAPE1 
FIG. 7. Comparison of human APEl and exonuclease III 
from Escherichia coli. The structurally similar enzymes, 
human APEl (PDB identifier, 1 BIX, green ribbon rendering) 
and exonuclease III (PDB identifier, lAKO, blue), share a 
similar fold; however, APEl includes an additional 62 N-
tenninal residues, highlighted in red (residues 44-62). In 
exonuclease TIT, the residue equivalent to the APE1 Cys 65 
(yellmv stick rendering) L5 Val 4 (gray stick rendering). (For 
interpretation of the references to color in this figure legend, 
the reader is referred to the web version of this article at 
WW\-v.l iebertonline.com/ ars). 
1254 
FIG. 8. Compar ison of active-site regions of human APEl 
and exonuclease III. Stick renderings are shown for residues 
within the active sites of APEl (PDB identifier, lBIX, green 
ribbon rendering) and exonuclease III (PDB identifier, lAKO, 
blue). Active-site residues are color coded as follows: light 
blue, Asn; slate blue, Gln; blue, Asp; purple blue, Glu; red, His; 
green, Tyr; light orange, Phe; bright orange, Trp; yellow, Leu; 
pale yellow, Ile. The active-site regions of APEl and exonu-
clease III are highly conserved. (For interpretation of the re-
ferences to color in this figure legend, the reader is referred to 
the web version of this article at www.liebertonline.com/ ars). 
the hAPEl and the E. coli enzyme is llinited to Cys 208 and 
Cys 310, but within vertebrate APEs, all Cys residues except 
Cys 65 and Cys138 are conserved (68). The structure of APE in 
vertebrates also is conserved, based on a comparison of the 
zAPE and human APEl structures. Within the vicinity of Thr 
hAPE1 N-terminus 
FIG. 9. Comparison of zebrafish APE and human APEl. 
Although the zebra fish APE (PDB identifier, 203C, light gray) 
also includes an extended N-terminus similar to that found 
in the human APEl (PDB identifier, 203H, dark gray), it does 
not have redox activity. As sho~vn in these ribbon render-
ings, the zebrafish and human enzymes are structurally very 
similar, including the N-terminal residues. Conserved Cys 
residues, including 93, 99, 208, 296, and 310, are shown in 
black stick rende1ings for the human enzyme. 
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FIG. 10. Positions of Cys residues within APEl. The 
human APEl (PDB identifier, lBIX, gray ribbon rendering) 
includes seven Cys residues (black sticks), whose positions 
relative to the active-site His 309 are sho~vn. None of the Cys 
residues is appropriately positioned to form a disulfide 
bond, and the redox-critical Cys residue, Cys 65, is a buried 
residue located in the first P strand of the APEl fold. 
58, the structure and chemical environment is highly con-
served (68). In contrast, residues in the vicinity of Val 4 in the 
E. coli enzyme exonuclease TIT are not similar to those found in 
the vertebrate APEs. 
The report of a viable C64A knockin mouse and data \<vi thin 
challenged the validity of a role for Cys 65 in the redox activity 
of APEl (148). However, \<Ve note that the mouse knockin 
study does not directly address the role of Cys 65 (64 in 
mouse) in the redox activity, but rather suggests that Cys 65 is 
not essential for the development of the mouse, potentially 
confirming that redox systems are red1mdant. In an effort to 
clarify this issue, we substituted Thr 58 with Cys in zAPE, 
thereby conferring redox activity to the enzyme, as measured 
both in EMSA redox and transactivation redox assays (68). 
To date, the preponderance of evidence supports a role for 
Cys 65 in the red ox activity of hA PE1 . Thus, we conclude that 
evolution of redox activity in hAPEl is coincident with the 
appearance of Cys 65 in mammalian sequences. 
B. Comparison of APE1 with other redox factors 
ln contrast to molecules such as TRX and GIV<, which 
maintain the general redox status of the cell, APEI does not 
contain t'~'O Cys residues within a C-X-X-C motif. Thus, the 
mechanism by which APE1 reduces transcription factors is 
likely to differ from that of thioredoxin or glutaredoxins. In 
the crystal structures reported to date of APEI, no disulfide 
bonds are present, and the only Cys residue reported to be 
absolutely required for redox activity is Cys 65, which is a 
buried residue. The Cys residues positioned closest to one 
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Local unfolding of C-terminus in oxidized PRX 
C-terminal region in reduced PRX 
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FIG. 11. Redox mechanism of peroxiredoxin (PRX) involves local unfolding. Peroxiredoxin is the enzyme responsible for 
detoxification of hydrogen peroxide. In a mechanism dissimilar to that used by TRX or GRX, PRX has two Cys residues, one 
located in each subunit of the dimeric structure, which participate in the reduction of hydrogen peroxide, leading to the 
for1nation of disulfide bond in PRX. Reduced PRXII (PDB identifier, lQMV) is shown in the left panel as a ribbon rendering 
with one subunit in light gray, the second in dark gray, and Cys residues in black. Tn the right panel, the oxidized PRXI (PDB 
identifier, 1QQ2) is rendered similarly. Unfolding of the C-te:minus of the dark-gray subunit allows the formation of a 
disulfide bond between the Cys residues that are located ~9 A apart in the reduced form of the protein. 
another are 93 and 208, but their respective S atoms are ~3.5 
A apart, too far apart to fom1 a disulfide bond, which is typ-
ically ~2.2 A in length. Further, these residues are buried in 
the core of the protein and are not accessible. The solvent-
accessible Cys residues include 99 and 138; however, these 
residues are not in close proximity to one another and would 
not be expected to interact to form a disulfide bond. Fur-
the1more, substitution of Ala for either Cys 99or138 has no 
effect on redox activity (178). Before the determination of the 
crystal structure of APEl, it was proposed that Cys 65 and 93 
form a disulfide bond (178). Given the respective locations of 
• Cys 65 and Cys 93 in the protein, > 8 A apart and positioned 
on opposite sides of the {3 sheet (Fig. 10), a substantial con-
formational change in the structure of the protein would be 
required for a disulfide bond to form between these residues. 
Another group of redox proteins, peroxiredoxins, are re-
sponsible for sensing hydrogen peroxide in the cell and serve 
as catalysts to detoxify this extremely reactive molecule (87). 
These enzymes are dissimilar to thioredoxin- or glutaredoxin-
type molecules in that they lack a C-X-X-C n1otif, but they do 
include two Cys residues that are required for activity (183). 
These Cys residues are located ~9 A from one another in the 
fully folded dimeric stn1cture (Fig. 11); one Cys from each 
monomer forms the active site (183). The nucleophilic thiolate 
is sequestered before a local unfolding event near the dimer 
interface. The resolving thiolate is located near the C-terminus 
of the molecule and, on local unfolding, is placed in close 
proximity to the nucleophilic thiolate (183) (Fig. 11 ). Peroxir-
edoxins reduce hydrogen peroxide and not other proteins 
(87), but on overoxidation to the sulfenic or sulfinic acid state, 
are themselves reduced by sulfiredoxin (29, 177). The re-
quirement for local unfolding for peroxiredoxin to complete 
its catalytic cycle in the detoxification of hydrogen peroxide is 
very interesting and may be a general mechanism used by 
other redox factors. Although APEl does not include two Cys 
residues positioned similarly to those found in peroxiredoxin, 
the possibility remains that a conformational change or local 
unfolding event may result in more favorable positioning of 
Cys residues. An interesting similarity bet\~reen APEl and 
peroxiredoxin is the proximity of a C ys residue to a terminus; 
in the case of hAPEl, Cys 65 is located relatively close to the 
N-terminus of the protein; it is located \~rithin the first sec-
ondary stn1ctural element (a /3 strand) in the fold (Fig. 7). Tn 
summary, we conclude that hAPEl is unique as a redox fac-
tor, having evolved this additional function while maintain-
ing its essential base-excision repair activity. 
C. Mechanism of redox regulation by APE1 
Although a role for Cys 65 in the redox activity of hAPEl 
has been established (68, 178), a detailed mec11anismhas yet to 
be elucidated. Jt is possible that another as-yet-unidentified 
Cys residue in APEl is involved in the redox activity. In this 
case, after the formation of a mixed disulfide intermediate 
beh.veen Al)El and a transcription factor, a resolving Cys 
would serve to restore the thiolates in the transcription factor. 
As noted earlier, this interaction would likely involve a dif-
ferent conformation of hAPE1 than has been reported in the 
crystal structures to date (17, 68, 70, 139). Alternatively, a 
residue other than Cys might be involved in the redox activ-
ity, perhaps a Ser residue, as found in some glutaredoxins. A 
similar mechanism would be proposed in this case, although 
involvement of a Ser residue ;vould require a significant re-
duction in its pK •. As the stoichiometry of the relevant redox 
complex has yet to be established, it is possible that more than 
one APEl molecule is involved in the reduction of transcrip-
tion factors. In this case, a Cys or Ser from a second molecule 
of APEl may serve as the resolving thiolate, again, in a 
mechanisn1 similar to that p roposed for thioredoxin. As this 
problem is of considerable interest, we are actively investi-
gating the mechanism of redox regulation by hAPE1. 
V. Transcription Factors Regulated 
by the Redox Activity of APE1 
Because APEl is a multifunctional protein involved in both 
the repair of DNA damaged by oxidative or alkylating com-
poimds and in the redox regulation of a nurnber of stress-
inducible h·anscription factors, such as AP-1, NF-KB, HIF-lo:, 
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FIG. 12. Structural comparison of DNA-binding domains 
from transcription factors that are reported to be redox 
regulated b y APEl/Ref-1 bound to DNA. Proteins are 
shov.rn in a gray ribbon rendering, and the DNA in a spline/ 
stick representation in black. The DNA-binding domains of 
the leucine zipper-motif protein AP-1 (c-Jw1/c-Fos) bound to 
DNA (PDB identifier lFOS) is shown in (A), the immuno-
globulin-like fold of p53 (PDB identifier 1 TSR) with an a 
helix bound in the major groove (B), and the heterodinieric 
two-domain imn1unoglobulin-like folds of p65/ p50 NF-KB 
(PDB identifier 1VKX) in (C). A representative basic leucine-
zipper/ basic helix-loop-helix-containing protein (MyoD) 
bound to DNA (PDB identifier lMDY) is shown in (D) to 
illustrate the type of interaction expected for HIF-la bound 
to DNA. 
and p53, it clearly plays a pivotal role between redoxsignaling 
that alters the cellular response to DNA damage and DNA-
repair functions. These transcription factors are multido-
main proteins that are stntcturally unrelated, suggesting 
that no common structural motif is recognized by APEl. 
Further, the DNA-binding domains of these factors, which 
are redox regulated, are structurally distinct (Fig. 12); AP-1 is 
a heterodimeric bZip family protein; p53, a single immuno-
globt1lin-like domain; NF-KB, a di1ner of two-domain 
immunoglobulin-like subunits; and HlF-la, a basic helix-
loop-helix domain. Redox regulation of tra115cription factors 
serves as one of several mechanisms that control sequence-
specific DNA-binding and thereby gene expression. Of the 
transcription factors regulated by APEl that play an impor-
tant role in the DNA-damage response or DNA-repair path-
ways including DR, BER, HR, MMR and GGR, p53, AP-1, and 
HIF-la are discussed here. 
A. p53 
The tumor-suppressor p53 is a sequence-specific tran-
scription factor that serves as a potent tumor suppressor and 
functions in part by preserving genomic integiity (113). Not 
surprisingly, it has been demonstrated that p53 promotes 
genomic integrity by regulating some of the DNA-repair 
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pathways (80, 162). Regulation of DNA repair by p53 is 
complex, involving both transactivation-dependent and -in-
dependent mechanisms, revie,~red by Sengt1pta and Harris 
(162), and p53 is itself regulated by both redox-dependent and 
-independent mechanisms involving Ref-1 (APEl). 
lt1vestigation of redox regulation of p53 was initiated based 
on the finding that oxidized p53 bound DNA very poorly (75) 
and led to the discovery that Ref-1 was the factor responsible 
for enhancing the DNA-binding activity of '.vild-type p53 
(101 ). Although Ref-1 is believed to interact transiently '.vith 
p53, and this interaction has been detected only by far Wes-
tern analysis (67) and not by coimmunoprecipitation (101), 
Ref-1 stimulates DNA-binding activity in vitro and transacti-
vation in vivo by wild-type p53 (67, 101). The mechanis1n by 
which Ref-1 enhances the DNA-binding activity of p53 has 
not yet been fully elucidated but has been proposed to include 
redox-dependent activation of the DNA-binding domain, 
potentially through direct reduction of a disulfide bond, as 
well as a redox-independent interaction with the C-terminal 
regulatory domain of p53 (101). Most recently, Ref-1 \·vas 
sho,.vn to interact '.vith the tetramerization domain, promot-
ing formation of tetramers from dimers and thereby enhanc-
ing sequence-specific DNA-binding activity of p53 through a 
redox-independent mecha11ism (77). l~edox signaling involv-
ing p53 has also been shown to depend on a general redox 
factor as well as Ref-1. TRX has been shown to enhance 
stimulation of p53-dependent expression of p21 by Ref-1 
suggesting a link between TRX and Ref-1 in cellular response 
to oxidative stress (175). A summary of p53 regulation of DR, 
BER, NER, MMR, HR, and NHEJ repair pathways follows. 
BER is initiated by highly specialized DNA glycosylases 
that cleave the DNA base, creating an AP site, as discussed 
earlier. Regtilation of the BER path,<Vay by p53 involves both 
activation and negative regulation of BER enzymes under 
different conditions and in different cell lines. In response to y-
ra y treatment, p53 was demonstrated to promote activation of 
AAG. However, this initial step in BER was also shown to be 
under negative transcriptional regulation by p53 after expo-
sure to nitric oxide (NO) (202). Recent studies demonstrated 
that p53 downregulated APEl expression through binding to 
the promoter region of APEl that includes an SPl site. APEl 
mRNA and protein levels decreased in a time-dependent 
manner in the human colorectal cancer line HCTl 16 
p53( + / + ), but not in the isogenic p53-null mutant after 
treatment with camptothecin. Overexpression of v.rild-type 
p53 in the p53-null cells significantly reduced both endoge-
nous APEl and APEl promoter-dependent luciferase ex-
pression in a dose-dependent fashion (196). Thus, Ref-1 
(APEl) regulates DNA-binding of p53, and p53 in tu1n reg-
ulates both expression and protein levels of APEl in this 
example. 
Another BER enzyme, DNA polymerac;e P (pol fJ), involved 
in SP-BER, has been sho,~rn to be regttlated by p53. Pol p has 
associated dl~ lyase activity that is important and often rate 
limiting in BER and acts after APEl activity. Pol fJ also plays a 
role in single nucleotide gap filling in LP-BER. In p53-deficient 
cells, it has been sho,.vn that pol fJ protein expression is altered 
(35). Additionally, pol fJ gene expression in CHO cells and 
HeLa cells can be upregulated by CREB in response to DNA 
alkylating agent exposure (79). As discussed, CREB is under 
redox control for its binding to DNA and activating tran-
sc1iption. Therefore, a tight link and interaction occurs in the 
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TABLE 1. !~OLE OF APEl IN REGULATING EXPRESSION OF DNA REPAIR GENES 
Apel/Ref-1 
Transcription Factor 
NF kB 
Direct Repair 
ACT 
AP-1 
Hornologous Recombination 
A1M 
RADSO 
Global Geno1ne Repair 
ERCCl 
XPA 
RAD23B 
ERCC3 
Misrnatch I<epair 
MLHl 
MSH2 
PMS2 
MSH6 
CREB p53 
Direct Repair 
ACT 
Homologous l~econibination 
RADSl 
WRN 
Global Genome Repair 
Xl'C 
DDB2 
Misnzatch J<epair 
MLHl 
MSH2 
PCNA 
PMS2 
HJF-la 
Honzologous Recombination 
NBSl 
Mismatch l~epair 
MSH2 
MSH6 
Base Excision Repair 
UNC2 
Base Excision Repair 
Pol/3 
Base Excision Repair 
Pol/3 
DNA BER process between a nurnber of transcription factors 
that are under redox control and the DNA-repair response 
(Table 1). 
NER, which is divided into TCR and CCR, as discussed 
earlier, is affected differentially by p53. For example, several 
studies fotu1d that p53 selectively affected GGR, but not TCR. 
T\·vo main proteins in GGR, DDB2 and XPC, "''hich are in-
volved in DNA-damage recognition, are transcriptionally 
regulated by p53 (3, 96, 168). Loss of p53 and subsequent 
deficiencies in the CCR proteins DDB2 and XPC appear to 
lead to genome instability. This has been effectively demon-
strated in knockout mouse studies. In this study, lOOo/o of 
xpc·I· mice develop lung cancer, and DDB2·/· mice develop 
skin tumors (89). Again, if p53 is not fully functiona l through 
redox modification, it cannot turn on DDB2 and XPC, which 
would result in defective CGR (Table 1). 
MMI~, which is in charge of DNA repair after DNA 
polymerase errors, removes mismatches in DNA. MSH2 in 
complex '~1ith MSH6 or MSH3 is active in the recognition of 
single-base mismatches and short insertion/deletion mispairs 
or larger loops of unpaired nucleotides, respectively. MSH2, 
MLHI, and PMS2 have all been sho\.vn to be under p53 reg-
ulation, similar to DDB2 and XPC in NER (38, 159). PCNA, 
another member of the NER pathway, also is under p53 reg-
ulation (Table 1) (189). 
DSBs threaten severely genomic stability by facilitating 
deletion or translocation or both of chromosomal DNA. Be-
cause either a deficit or an excess in Hl~ may lead to genomic 
instability, it is not surprising that HR is highly regulated. 
Once again, p53 plays an important role in the repair of DSBs 
through the regulation of both DSB repair path\o\rays, HR and 
NHEJ. Increased levels of HR have been observed in mice that 
are deficient in wild-type p53 (26, 127). Arias-Lopez et al. (10) 
demonstrated that p53 inhibits HR through repression of 
RAD51 expression. Additionally, p53 has been demonstrated 
to repress the h·anscription of the RecQ4 helicases, WRN and 
RecQ4 (163, 191). 
APEl 
AAG 
Finally, some studies in murine fibroblast cell lines have 
demonstrated that AGT also is under p53 regulation (72, 155). 
ACT also appears to be regulated by NF-KB, another tran-
scription factor that is under redox control by APEl. This was 
demonstrated by overexpression of the p65 subunit of NF-KB 
in HEK293 cells, resulting in an increase in AGT expression 
(116). 
All of these studies point to the possible relevance of redox 
controlling DNA-repair responses through p53. Therefore, if 
reduced p53 is required to bind DNA and either activate or 
repress the transcription of DNA-repair genes, as discussed 
earlier, then it follo>vs that Ref-1 (APEI) plays an i.J.nportant 
role not only in the redox modulation of p53 but also in the 
regulation of DNA repair. 
B. AP-1 
Activator protein-I (AP-1) refers to a family of structurally 
and functionally related basic leucine zipper proteins (bZIPs) 
that intermix to form heterodimeric sequence-specific DNA-
binding proteins, including primarily Jun proteins, c-Jnn, 
JunB, and JnnD, Fos proteins, c-Fos, FosB, Fra-1 and Fra-2, 
and some ATP-family members, ATFa, ATF-2, and ATF-3 
(82). These proteins recognize AP-1 sites that are also refen·ed 
to as tetradecanoylphorbol-13-acetate {TPA)-responsive ele-
ments. AP-1 transcription factors are inducible factors that 
respond to environmental changes, including stress and ra-
diation, or to growth-factors signals. Proliferation, differenti-
ation, apoptosis, and transformation are some of the processes 
that are mediated by AP-1 (82). 
The first report of red ox activity associated with APE1 and 
its identification as Ref-1 resulted from efforts to identify the 
nuclear factor responsible for reducing AP-1 (c-Jun/c-Fos) and 
thereby enhancing its DNA-binding activity (1, 184). l{edox 
regulation of AP-1 was found to result from oxidation/ 
reduction of conserved Cys residues within the basic DNA-
binding domains of c-Jun and c-Fos (AP-1) (2). Oxidized AP-l 
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shows little affinity for DNA as compared with reduced AP-1. 
c-Fos and c-Jun di.Jnerize through a coiled-coil interaction 
involving the leucine-zipper motifs and bind DNA as a het-
erodimer; c-Jun also forms a homodimeric species with lo,.ver 
DNA-binding affinity than the heterodimeric c-Jun/ c-Fos, 
whereas c-Fos does not exhibit any DNA-binding activity on 
its O\.Vn (2). The conserved C ys residue within c-Jun is mutated 
to a Ser residue in the oncogenic v-Jun, ""hich is constitutively 
active and exhibits enhanced DNA-binding relative to c-Jun 
(2). Thus, Ref-1 regulates DNA binding of AP-1 in a redox-
dependent manner involving direct reduction of the con-
served Cys residues within the DNA-bi11ding domams of 
c-Jun and c-Fos. l~ef-1 has been shown to copurify wifu AP-1 
(184) and thus interacts more stably ""ith this transcription 
factor than '.vith p53. TRX has also been identified as a factor 
modulating transcriptional activation of AP-1 through its re-
duction of Ref-1 (83). As sttmmarized later, AP-1, which is 
rapidly i11duced in response to a number of cellular stimuli, 
regulates fue expression of several protems involved pri-
marily in NER and MMR DNA-repail· pathways. 
Tn one example of regulation of DNA-repair proteins by 
AP-1 composed of c-Jun and ATF2, Hayakav.ra et al. (78) 
identified 23 DNA-repair or repair-associated genes whose 
promoters are bound on phosphorylation of ATF2 and c-Jun 
after cisplatin treatment. These genes were identified by usi11g 
chromatin inununoprecipitation (ChIP) vvifu antibodies 
against A TF2 and c-Jun, follo,~red by hybridization to pro-
moter arrays (78). These include ERCCl, ERCC3, XPA, MSH2, 
MSH6, RAD50, RAD23B, MLHl, PMS2, UNG2, and ATM. 
Confirmatory studies directly established expression of some 
genes, including ERCCl, ERCC3, XP A, RAD23B, and MSH2, 
and so1ne genes that have been specifically in1plicated in fue 
repair of DNA-cisplatin adducts, such as RAD23B, XPA, 
ERCC3, XPF-ERCCl, MSH2, and PMS2. DNA adducts in-
duced by dsplatin are repaired mainly by fue NER pafuway. 
Several important proteins including XI' A, I~D23B, El~CCl, 
and ERCC3 in NER were observed on the promoter array. The 
members of the MMR complex, including MSH2, MSH6, 
MLHl, and PMS2, which are included in a large complex 
involved in the recognition of DNA-cic;platin adducts, are 
bound strongly by activated c-Jun or ATF2 or bofu. AP-1 also 
was discovered to upregulate MSH2 expression i.11 the mye-
loid leukeinia U937 cell line treated with a phorbol ester (TPA) 
(95). Undeniably, ERCCl has been recognized to be regulated 
by AP-1. Li et al. (119) demonstrated that AP-l is transcrip-
tionally up-regulated ERCC-1 in response to TPA in human 
ovarian cancer cells (119). 
All of fuese studies support fue role of fue involveinent of 
AP-1 in regulating a significant nu1nber of DNA-repair pro-
teins fuat are involved mainly in fue NER and MMR path-
ways (Table 1). Because AP-1 must be converted from an 
oxidized to a reduced state to bind to its target sequence, 
redox control of thic; protein would have significant implica-
tions. As for p53, APEl is implicated as a potential poi11t of 
control for regulating the DNA-binding activity of AP-1 and 
thereby n1odulating the expression of DNA-repair protems. 
C. HIF-1CJ. and hypoxia 
Hypoxia-i11ducible factor - 1 (HJF-1) is a heterodirneric 
transcription factor con1p1isrng HIF-la and HIF-1/J (also 
known as aryl hydrocarbon-receptor nuclear h·anslocator) 
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subunits (93) that plays an important role under hypoxic 
conditions in the cell. Of fue two subunits, HIF-lCt. has been 
sho,.vn to be crucial for regulating cellular response to hypoxia 
and is frequently overexpressed in ht1man cancers. Under 
normal oxygen conditions, HIF-la is targeted for ubiquitin-
mediated proteasomal degradation by von Rippel-Landau 
protein (pVHL) (97, 98, 132). Under hypoxic conditions, HIF-
la translocates to fue nucleus and dimerizes with HIF-1/J, 
forming HlF-1. HTF-1, along '"'ith coactivators, binds hypoxia-
response elements (HREs) within promoters and regulates the 
expression of its downstream genes, including vascular en-
dothelial growfu factor (VEGF) (62, 102). The DNA-bindi11g 
activity of HIF-1 has been shown to be regulated by redox 
signali11g, and the redox-dependent stabilization of the HIF-
1a protein is required for activation of HIF-1 (93). Over-
expression of TRX and Ref-1 enhanced the DNA-binding 
activity of HJF-1, as detected in a reporter assay. The results, 
taken togefuer, suggest a role for I~ef-1 as a redox regulator of 
HIF-la. l~ef-1 (APE-1) also has been shown to be required for 
the binding of transc1iptional protei11s to fue HIF-1 DNA-
recognition element within the rat pulmonary artery endo-
thelial cell VEGF gene (198). Alfuough thic; study did not 
specifically address the role of redox regulation, fue authors 
found fuat l{ef-1 was required for the formation of the hyp-
oxia-inducible transc1iptional complex, includi11g HIF-1 and 
transcriptional coactivators, p300 and cyclic AMP response 
element-binding protein (CREB). Tn a second example of Ref-
1 as a coactivator, a transcriptional complex including HIP-la, 
signal and transducer of transcription 3 (ST AT3), CREB-
binding protein (CBP)/ p300, and l~ef-1 (APEl) was reported 
to regulate the protein tyrosine kinase Src-dependent ex-
pression of VEGF in response to hypoxia in pancreatic and 
prostate carcinomas (71). More recently, HTF-1Ct. was shown 
to play a role in downregulating mRNA and protein levels of 
I~ef-1 w1der hypoxic conditions in human microvascular en-
dofuelial cells (125). Thus, HIF-lo: regulates expression levels 
of Ref-1 and is itself regulated by Ref-1. 
Increasing evidence reveals fuat hypoxic stress in fue tumor 
microenvironment can cause genetic instability in cancer cells. 
Hypoxia induces changes in the expression of several genes 
involved in DNA-repair pathways. These shtdies suggest that 
hypoxia downregulates the expression of key genes '"'ithin 
fue MMR pathway, including MLHl and MSH2, and several 
critical mediators of HR, BRCAl, BRCA2, and RAD51, re-
sulting in significant genetic instability (21, 22, 24, 25, 32, 109, 
135, 138) [reviewed in Bindra et al., 2007(23), and Bristow and 
Hill, 2008 (32)]. The MMR genes appear to be repressed 
through a mechanism involvi11g c-Myc (25). 
In most studies, repression of MMR and HR has been 
sho•vn to be independent of HIF-lo: (21, 22, 24, 25, 32, 135, 
138). However, this has been contradicted by Koshiji et al. 
(109), who demonstrated that HJF-la is responsible for genetic 
instability during hypoxia at the nucleotide level by inhibiting 
MSH2 and MSH6, which recognize DNA base mismatches. 
These investigators demonsh·ated fuat HIF-lc.< displaces fue 
transcriptional activator Myc fro1n Spl binding to repress 
MSH2-MSH6 in a p53-dependent manner (109). HTF-1a also 
has been shown to be associated with the loss of MSH2 ex-
pression in human sporadic colon cancers (172), linking 
hypoxia to DNA repair in fue induction of these cancers. The 
decrease of the expression of NBSl, a member of fue MRell-
RAD50-NBS1 (MRN) complex that illitially recognizes DNA 
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DSBs, has also been shown to be HlF-la dependent (173). 
These studies dei11onstrate that the regulation of DNA repair 
is an integral part of the hypoxic response and that hypoxia 
affects DNA repair partially through HTF-1a, a critical medi-
ator in the hypoxic response (Table 1). As Ref-1 has been 
implicated in the redox regulation of HIF-la, it then aLc;o plays 
a role in the regulation of DNA-repair genes controlled by 
HIF-l o:. 
VI. The Multifunctional APE1 and Redox Control 
APEl is a vital multifunctional protein that acts as an 
essential master regulator contributing to the maintenance of 
the geno1ne stability (Fig. 6). Functional activities associated 
with APE1 include apu1inic/ apyrimidinic endonuclease ac-
tivity essential for BER, redox activity, transcriptional regu-
latory activity (19), and most recently, RNA- cleavage activity 
(15, 176). In this review, we have limited our discussion to the 
APEl BER repair and redox activities, the functions relevant 
to redox regulation of DNA repair. APEl also is subject to a 
nttmber of interesting posttranslational modifications, in-
cluding acetylation, phosphorylation, and nitrosylation. The 
implications of these modifications \.Vere reviewed recently 
(19, 171) and are not further discussed here. 
APEl has a pleiotropic role in controlling cellular response 
to oxidative stress. In addition to its repair function in BER as 
an AP endonuclease, APE1 controls the redox status of either 
ubiquitous (i.e., AP-1, Egr-1, NF-KB, p53, CREB, HIF-lo:) or 
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tissue-specific transcription factors (i.e., PEBP-2, Pax-5 and 
-8, and TIF-1) (Fig. 6) (6, 35, 48, 84, 94, 112, 169, 175, 184, 185). 
ROS indticed by different oxidative or toxic agents have 
been shown to increase APE1 expression transiently (Fig. 13). 
A number of transcription factors, including Egr-1, CREB, and 
Jun/ ATF4, are involved in the inducible expression of APEl 
(66, 73, 152). In a recent study, the level of APEl was shown to 
be increased h·anscriptionally in response to ROS in mela-
noma cells by microphthalmia-associated transcription factor 
(MiTF), a key transcription factor for melanocyte lineage 
survival that plays an important role in development and 
carcinogenesis (122). In this study, melanoma cells were 
classified into MiTF-positive and -negative groups to explore 
the function of MiTF in regulating cellular responses to ROS. 
A high level of APE1 / Ref-1 was discovered in the MiTF-
positive melanoma cell lines. Knocking down MiTF reduced 
the APEl protein level and abolished induction of APEl by 
l{OS. MiTF-negative melanoma cells survived more poorly 
under ROS stress than did the MiTF-positive cells. Over-
expression of APEl partially rescued ROS-induced cell death 
when MiTF '.vas depleted. The MiTF regulation of APE1 is 
direct through E-boxes on the APEl promoter. It alc;o was 
found that exposure of HeLa cellc; to H20 2 and to hic;tone 
deacetylase inhibitors increases acetylation of APEl at resi-
dues Lys6/ Lys7, leading to Egr-1-mediated induction of the 
tumor-suppressor PTEN gene expression (52). In addition, 
increasing evidence demonstrates that functional triggering 
of membrane-bound receptors (such as TSH, CD40L, ATP, 
TRX Kinases 
ERK1/2 
APE1/Ref-1 
FIG. 13. Overview of ROS signaling. Reactive oxygen species (ROS) are generated through external stimuli or stress, as 
well as n1etabolic processes, and act as a signal for )NK and ERKl/ 2 kinases, resulting in the activation of a number of 
transcription factors, including Egr-1, CREB, and Jun/ ATF4, which are involved in the inducible expression of APEl. In 
melanoma cells, MiTF also was shown to upregulate transcription of APE1. In its role as a redox factor, APEl reduces a 
number of transcription factors, including AP-1, Egr-1, NF-KB, p53, CREB, and HJF-la. Thus, APEl controls the redox status 
of several transcription factors that in turn regulate expression of APEl. (For interpretation of the references to color in this 
figure legend, the reader is referred to the web version of this article at w\~1w.liebertonline.com/ars). 
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IL-2) can lead to Al)El functional activation through intra-
cellular generation of sublethal doses of ROS (170). APEl also 
is directly responsible for the conh·ol of the intracellular ROS 
levels through inhibiting the ubiquitous sma II GTPase Rael, 
the regulatory subunit of NADPH oxidase system (9, 149). 
Recently, Park et al. (151) found that overexpressing APEl/ 
I~ef-1 increased inhibition of angiotensin Il (Ang II) to the 
whole-cell conductance Ca2 - -activated K+ (BKca) currents in 
human umbilical vein endothelial cells (HUVECs) through 
blocking NADPH oxidase-dependent ROS production. The 
inhibitory effect of Ang II on BKca channel function is 
NADPH oxidase dependent (151). It also was demonstrated 
that NADPH-mediated ROS production induced by the P2Y 
purinergic receptor triggering was able to promote APEl 
h.1nctional activation (152) and results in the proposition of an 
autoregulatory loop between these tl.vo systems. 
We demonstrated that reducing expression of APEl in 
neuronal cultures by using small interfering l~A (siRNA) 
enhances cisplatin-induced ROS generation, cell killing, and 
apoptosis (103, 136). Another recent study showed that Apel 
can antagonize the generation of ROS. Overexpression of 
APEl inhibits, ""hereas silencing APEl expression potentiates 
ROS accumulation under treatment with oxidative reagents 
or loading with granzyme K in cytotoxic T lymphocyte 
(CTL)/ natural killer (NK) cells. APEl is a physiological sub-
sh·ate of granzyme K, and cleavage by granzyme K facilitates 
inb·acellular ROS accumulation and enhances granzyme 
K-induced cell death (74). Merluzzi et al. (136) also fotmd that 
repression of APEl by antisense overexpression determines 
an additional increase in CD40-mediated B-cell proliferation, 
and the increase is abolished by pretreatment of cells with the 
antioxidant N-acetyl-L-cysteine (NAC). They proposed that 
APEl, through control of the intracellular redox state, may 
also affect the cell cycle by inducing nucleus-cytoplasm re-
distribution of p21 (136). 
A genetic study has demonstrated that APEl is essential for 
cell survival and organism development. Knockout of APEl 
in mice leads to postimplantation embryonic lethality on days 
ES to E9 (188). Conditional knockout and knockdown strate-
gies also confirmed the crucial role of this protein in cellc; (58, 
65, 99). In addition, studies demonstrated that altering APEl 
levels leads to a change of cell growth, survival, and sensi-
tivity (28, 37, 56, 58, 81, 115, 134, 147, 179, 180). Hovvever, 
these studies used either overexpression of APEl, APEl an-
tisense oligonucleotides, or APE1 siRNA to change the total 
amount of cellular APEl and thereby all functions of APEl, 
including its repair and redox activities. Thus, the function of 
APEl involved in each case of altered cellular function caimot 
be identified. Because APEl plays co1nplex and c1itical roles in 
cell survival, proliferation, differentiation, and apoptosis in 
physiologic and pathologic conditions, as '~'ell as in the 
gro~rth and development of the organic;m, it is important to 
distinguish and characterize which function of APEl is in-
volved in different biologic events, especially those that may 
differ in no1mal cells and various pathologic cells, such as 
cancer cells. The use of specific small-molecule inhibitors 
blocking either repair or redox, but not both functions of 
APEl, ,.vi.II give a clearer picture and will be helpful for 
modifying its ftmcti.on in treatment of the different diseases. 
Our recent data demonstrated that £3330, 2E-3-[5-(2, 3 di-
methoxy-6-methyl-1,4-benzoquinolyl)]-2-nonyl-2-propenoic 
acid]), a novel quinone derivative, specifically blocks the re-
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dox function of Al'El and has no effect on APEl-repair ac-
tivity and other members of the BER pathway (128). By using 
£3330, we demonstrated that APEl is required in normal 
embryonic hematopoiesis and that the redox function, but 
not repair activity, of APEl is critical in normal embryonic 
hematopoietic development (199). 
VII. Modulating APE1 Activities 
as a Cancer Therapeutic Approach 
Elevated APEl levels have been demonstrated in a variety 
of cancers and are typically associated with aggressive pro-
liferation, increased resistance to therapeutic agents, and poor 
prognosis (SO, 140, 180, 190). Previous studies demonstrated 
that decreasing APEl / Ref-1 levels leads to the blockage of 
cell growth and the increase of cellular sensitivity to DNA-
damage agents by using anti-sense oligonucleotides and 
sil~NA of APE1 /l~ef-1 (56, 58, 115, 147, 180). Not yet known is 
the relative importance of APEl redox versus the repair 
function in cancer. Effo1ts to determine the effects of inhibiting 
either the redox or repair function of APEl are ongoing. 
Targeting of a specific protein, particularly one that plays an 
important role in cellular response to stress, by chemical 
knockout (i.e., through use of a small-molecule inhibitor) may 
have unintended consequences. However, exploration of 
novel targets is clearly ai1 avenue that n1erits pursuit, partic-
ularly in the case of cancers for which current treatments are 
ineffective. There has been considerable debate in the litera-
ture regarding the wisdom of inhibiting essential DNA-repair 
enzymes (14, 42, 57, 106, 129). However, small-molecule in-
hibitors have been identified for several DNA-repair en-
zyines, including MGMT, poly ADP-ribose polymerase 
(PARP1), ataxia-telangiectasia mutated kinase (A TM kinase), 
APEl, and DNA PKcs (42, 57, 129). Targeting of the redox 
function of Al)El represents a novel approach iI1 the devel-
opment of a cancer therapeutic agent. Blocking of the redox 
function of APEl would be expected to affect the activity of a 
number of downstream transcription factors and the gene 
products that they regulate. In this section, we focus primarily 
on redox inhibitors, those kno\.vn specifically to inhibit APEl 
and those that may affect APEl either directly or indirectly. 
We briefly discuss Al'El-repair iilhibitors as they have been 
reviewed recently (106). 
A. APE1 redox inhibitors 
1. E3330. One molecule previously discussed '.vas 
demonstrated to biI1d specifically to APEl with a biI1ding 
constant esti.Inated by surface plasmon resonance analysis 
(SPR) of 1.6 nM, which suggests a specific interaction betl.veen 
APEl and E3330 (166). We recently dem.onstrated that E3330 
blocks the redox h.mcti.on of APEl with AP-1 as the down-
stream target in vitro, as well as after the treatment of ovarian 
cancer cells with E3330 (128). Additionally, we found that 
£3330 blocks APEl redox activity ~1ith HIF-let. and other 
downstream transcription factors (Table 1 ). This demon-
strates that the redox inhibition is not specific for the do,.vn-
stream target. Although E3330 blocked the redox function of 
APEl, it had no effect on APEl-repair endonuclease activity. 
We also found that £3330 does have single-agent cancer cell-
killing abilities in a variety of cancer cell lines representing 
ova1ian, colon, lung, breast, brain, pancreatic, prostate, and 
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multiple myeloma cancers, but does not have significant cell 
killing in our studies with normal cells, such as emb1yonic 
hematopoiesis cells, retinal vascular endothelial cells 
(RVECs), and human CD34+ progenitor cells. These data 
implicate the redox role of APE in cancer, but not in "normal" 
cell survival. Inhibition of the APEl redox function signifi-
cantly attenuates I~VEC proliferation and capillary formation 
in vitro but does not cause cell death. Furthermore, the capil-
lary formation of RVECs appears n1uch more sensitive to re-
dox inhibition of APEl than to the proliferation. This is the 
first time that this role of APEl has been clearly demonstrated. 
Additionally, our data demonstrate a new role of APEl in 
angiogenesis, and inhibition of APEl red ox function by E3330 
abrogates this role (128). E3330 also has been shown to inhibit 
the gro,~rth of pancreatic cancer cell lines, an effect that is 
enhanced under hypoxic conditions (200), as well as pancre-
atic cancer-associated endothelial and endothelial progenitor 
cells (201). Consistent with redox regulation by l~ef-1, the 
DNA-binding activity of HIF-1 is inhibited by £3330 in the 
aforementioned pancreatic cancer studies. TI1us, collectively 
our data and those of others suggest that APEl redox function 
will be a promising target of cancer treatment and will open a 
new avenue for cancer treatment. 
2. Other redox inhibitors. A number of natural products 
reported to affect either directly or indirectly the redox func-
tion of APEl in cells were recently revie~red (57, 107, 128, 133) 
and are therefore discussed only briefly here. Soy isoflavones, 
a component in soybeans, are thought to have potential as 
chemopreventive agents in prostate cancer (137). Treatment of 
PC-3 prostate cells and xenograft mice with soy isoflavones 
after radiation treabnent resulted in increased cell killing, 
reduced NF-KB binding to DNA, and reduced APEl levels. 
The authors concluded that the soy isoflavones reduced APEl 
levels and subsequently resulted in a reduction of the ability 
of Al'El to reduce NF-KB, resulting in the inability of the cells 
to respond to the stress (156). Ho>vever, at this point, the data 
are merely co1Telative. 
Another nah1ral product, resveratrol, a component of red 
wine and grapes, was reported to affect the redox activity of 
APEl (193). Resveratrol was shown to inhibit both the endo-
nuclease activity of APEl and the DNA-binding activities of 
AP-1 in cellular extracts, presumably through inhibition of 
APEl redox function. However, this has not been corrobo-
rated by others, nor has it been shown to be effective at levels 
that are physiologically relevant. 
B. APE1 repair inhibitors 
To date, t>vo different classes of small molecules have been 
reported to inhibit the AP endonuclease activity of APEl, 
methoxyarnine (18, 124) and negatively charged molecules 
including CRT0044876 (130), an aryl stibonic acid 13755 
(161), and a number of pharmacophore-based compounds 
(197). Methoxyamine (MX) blocks repair by reacting with 
apurinic/ apyrirnidinic sites in the DNA and fom1ing stable 
adducts that prevent endonucleolytic cleavage by APEl (18, 
64, 124). As MX acts at the level of the DNA, it would also be 
expected to block the activity of other DNA-repair enzymes 
such as DNA polymerase f3 activity. However, none of the 
aforementioned co1npounds has been repo1ted to inhibit the 
redox activity of APEl; this is not discussed further here. A 
1261 
number of recent reviews discuss the status of these types of 
agents (14, 57, 106). 
VIII. Chemoprevention, Redox Modulation, 
and DNA Repair 
As was clearly documented, DNA dainage leading to 
genome instability is a key step for the initiation and pro-
gression of cancer (16). Both endogenous and exogenous 
DNA-damaging agents and particularly those that induce 
oxidative stress are some of the main factors that cause DNA 
damage in cells. Therefore, agents that reduce the oxidative 
stress and subsequent DNA damage, as >veil as those that 
increase the repair of DNA damage, are considered to be 
pertinent in cancer prevention. It is estimated that nearly one 
third of all cancer deaths in the United States could be pre-
vented. Accumulating research evidence has shown that some 
dietary antioxidants are able to reduce the incidence of cancer 
by increasing DNA repair and reducing oxidative stress. 
A. Dietary antioxidants 
1. Ellagic acid. Ellagic acid, a con1ponent in berries 
(bh.ieberry, strawberry, and red raspberry), was reported to 
reduce oxidative DNA damage both in vitro and in vivo (4, 5). 
In vitro, ellagic acid has demonstrated a >95°/o inhibition of 
8-oxodeoxyguosine (8-oxodG) production. It also was shown 
to reduce other oxidative DNA adducts caused by 4-hydroxy-
17 /j-esh·adiol and CuC12. In an in vivo study, female CD-1 mice 
were fed pure ellagic acid, and formation of DNA adducts 
was related to ellagic acid in a dose-dependent manner. Fur-
ther srudy found both ellagic acid and its narural source 
resulted in overexpression of genes involved in DNA-repair 
pathways such as XPA, ERCC5, and DNA ligase III, mainly 
those involved in NER. TI1ese results demonsh·ated that el-
lagic acid is effective in preventing oxidative DNA damage 
both in vitro and in vivo by increasing DNA repair. 
2. Selenium. Selenium is found in plentiful amounts in 
dairy, eggs, fish, meat, grains, and Brazil nuts. Selenium, in 
the form of selenocysteil1e, is a major constituent of many 
antioxidai1t enzymes known as selenoproteins. Not surpris-
ingly, Se was reported to be preventive for cancer initiation 
frorn oxidative DNA damage through reducing oxidative 
stress and increasing DNA repair. The active species of Se 
include hydrogen selenide (H2Se) and its methylated metab-
olite, methylselenol (MeSeH), selenomethionine (SeMet), and 
selenoproteil1s. Se, in the form of selenomethionine, was re-
ported to promote BER activity by p53 activation in normal 
human fibroblasts in vitro (164). This sh1dy demonstrated that 
Se-induced p53 activation promotes BER activity by reducing 
specific cysteine residues in p53. A dominant-negative APEl 
redox mutant blocks reductive activation of p53 by Se. Se also 
was shown to stin1ulate the activity of a selenoprotein, 
thioredoxin reductase (TR) (165). These data suggest that Se 
reduces p53 through interactions involving TR, which re-
duces TRX and APEl, as well as redox interactions between 
APEl and p53. Se-induced activation of p53 is also dependent 
on the BI~CAl protein in recombinational repair, which is 
frequently mutated in fainilial breast cancer (55). It also was 
reported that Se inhibited DNA-binding activity of tran-
scription factors such as AP-1, NF-KB, SP-1, and SP-3, as '-veil 
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as the DNA-repair proteins XPA in the NEl~ pathway and 
formamidopyrimidine DNA glycosylase (FPG) in the BER 
pathway (27, 76, 131, 195). TI1ese data i.J.nply that Se 1nay re-
duce cancer incidence through modulating DNA repair, re-
dox status of cells, and the cellular transcriptional response to 
oxidative stress. It also suggests that the redox function of 
APEl is a major component of this interaction. Additional 
clinical studies have found an inverse relation beh~reen the 
levels of Se and the prevalence of several types of cancer. 
3. Oltipraz. Oltipraz (4-methyl-5-(pyrazinyl)-3H-l,2-
dithiole-3-thione), a synthetic dithiolethione, is similar to the 
thiolethione, an antioxidant component in cruciferous vege-
tables. Oltipraz has been shown to inhibit the development 
and progression of multiple organ tumors, includi.J.1g breast, 
bladder, colon, sto1nach, liver, lymph nodes, h.mg, pancreas, 
and skin, induced by a variety of stiucturally di.verse carcin-
ogens in preclinical studies (41 ). Clinical studies demon-
strated that oltipraz has minimal toxicity in humans and 
significant chemopreventive activity (41). Oltipraz increased 
NEI~ activity by decreasing platinum-DNA adducts, but not 
BER activity, as 1neasured by determining the levels of AP 
sites in HT29 colon adenocarcinoma cells (146). Further study 
found that oltipraz also increases APEl protein level and AP-1 
DNA-binding, ;vhich is partially dependent on APEl in HT29 
cells (194). Oltipraz also was shown to inhibit microvessel 
formation in both human and rodent bioassays in a dose-
dependent manner (158). These data suggest that the redox, 
not the repair, function of APE1 may be involved in chemo-
preventive effect of oltipraz. 
All of these compounds are natural agents that have been 
i.J.nplicated in protecting against cancer. 
B. Direct regulation of DNA repair 
by altered redox status of the cell 
The evolutionarily conserved enzyme glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) is a key redox-sensitive 
protein with an active-site cysteine sulfhydryl. GAPDH was 
shown to interact directly with APEl (13). By using recombi-
nant protei.J.lS, Azam et al. (13) found thatGAPDH interacts with 
APEl through the active-site cysteine 152 to convert the 
"oxidized" form of APEl to its reduced form and reestablishes 
the ability to cleave AP sites. This reduction process also en-
hanced the detection of APEl by anti-APE! antibodies, sug-
gesting a structural d1ange. siRNA knockdown of GAPDH in 
HCT116 cells enhanced sensitivity to the alkylating DNA-
dan1aging agent methyl methane sulfonate (.MMS), v.rhich 
produces AP site, and ina·eased the level of spontaneous AP 
sites in the genomic DNA. These data imply that GAPDH plays 
an i.J.nportant role in promoting BER activity by maintaining 
APEl, a key AP endonudease, in an active reduced state. 
OGGl, an 8-oxoG DNA glycosylase in the BEI~ pathway, is 
responsible for recognizing and repairing 8-oxoguanine 
(8-oxoG), a com1non and mutagenic fo1m of oxidized guanine 
in DNA. A recent study 1-vith human lymphoblastoid cells 
treated with cadmium resulted in an almost complete re-
duction in the 8-oxoG DNA glycosylase activity of OGGl, 
presumably because of an alteration in the redox status of the 
cells. OGGl activity returned to normal once the redox cel-
lular status was returned to normal. The reversible inactiva-
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ti.on of OGGl activity by cadmium was strictly associated 
with reversible oxidation of the protein, as demonstrated by 
the use of cysteine-modifying agents, such as diamide, 1-vith 
the pure protein and cn1de extracts (30). A frequently found 
polymorphism of OGG!, S326C OGGl, associated with can-
cer development, has been shown to have lower 8-oxoG DNA 
glycosylase activity, and the lower activity of OGG1-Cys326 is 
associated '~'ith the easy oxidation of Cys326 to form a dis-
ulfide bond (31). Tn this study, the 8-oxoG repair activity 1-vas 
analyzed in the cells and cell extracts of lymphoblastoid cell 
lines established from individuals carrying either Ser/ Ser or 
Cys/ Cys genotypes. The cells homozygous for the Cys variant 
display increased genetic instability, reduced 8-oxoG repair 
rates, and almost twofold lower basal 8-oxoG DNA glycosy-
lase activity in their cell extracts. Reducing agents increase the 
repair capacity to the level of the Ser va1iant, but do not affect 
the activity of the latter. The 8-oxoG DNA glycosylase activity 
in cells carryi.J.1g the Cys/ Cys alleles is more sensitive to oxi-
dizing agents (31). 
NER, which repairs mainly bulky DNA adducts and heli.x-
distorting lesions, has some crossover activity on oxidative 
DNA damage. On exposure of human pulmonary epithe-
lial cell<> (A549) to nontoxic doses of H20 2, increased expres-
sion of XP A, XPC, ERCC4, and EJ~CCS was observed, whereas 
ERCCl expression decreased (114). Functional studies also 
demonsti·ated a decrease in NER activity. 
Glutathione (GSH) also is directly implicated in the regu-
lation of NER. GSH-depletion in cells preincubated with BSO, 
L-buthionine-sulfoximine, completely abolished the down-
regulation of ERCC1 expression and the decrease in NER ca-
pacity by H 20 2 and increased significantly the upregulation 
of ERCC4 expression. These data suggest that NER capacity as 
well as the expression of NER-related genes can be modulated 
by oxidative stress (114). 
IX. Concluding Remarks 
Tn conclusion, redox regulation clearly plays an impor-
tant role in DNA repair, with implications for human health 
and cancer therapeutic development. We have highlighted 
the role of APEl, an important DNA-repair protein and 
redox factor, in this revie\·v as a protei.J.1 directly linking 
redox regulation and DNA repair. Tt is our expectation that 
future research in this area ~rill bring additional insights 
into the i.J.nportance of redox regulation in DNA repair and 
will likely result in the identification of other proteins that 
also play i.J.nportant roles i.J.1 redox regulation and DNA 
repair. 
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Abbreviations Used 
8-oxoG = 8-oxoguanine 
AAG = alkyladenine DNA glycosylase 
AGT = 0-6-alkylguanine-DNA methyltransferase 
Ang II = angiotensin II 
AP - apurinic/ apyrimidinic 
AP-1 = activator protein 1 
APEl = apurinic/apyrimidinic endonuclease 1 
ATF4 = activating transcription factor 4 
A TM = ataxia-tclangicctasia- mutated protein 
BER = base-excision repair 
BKca = large-conductance Ca2+ -activated K~ channels 
BLM - Bloom syndrome gene product 
BRCAl = breast cancer 1, early onset 
BRCA2 - breast cancer 2, early onset 
CD40L - CD40 ligand 
CREB = cyclic AMP response elen1ent-binding protein 
CSA = Cockayne syndrome protein A 
CSB = Cockayne syndrome protein B 
CTL = cytotoxic T ly1nphocyte 
DDBl = DNA damage binding protein 1 
DDB2 = DNA damage binding protein 2 
DNA-PI<c.. - DNA-dependent kinase catalytic subunit 
DR = direct repair 
dRP = deoxyribophosphate 
dRPase = deoxyribophosphodiesterase 
DSBs = double-strand breaks 
E3330 = 2E-3-[5-(2, 3 dinlethoxy-6-methyl-1,4-
benzoquinolyl))-2-nonyl-2-propenoic acid 
ERCCJ = excision-repair cross-co1nplementation group 1 
ERCC3 = excision-repair cross-complementation group 3 
ERCC5 - excision-repair cross-complementation group 5 
FENl = flap endonuclease 1 
FPG = formamidopyrimidine DNA glycosylase 
GAPDH = glyceraldehyde-3-phosphate dehydrogenase 
GGR = global genome repair 
GRX = glutaredoxin 
GSH = glutathione 
GSSG = glutathione disulfide 
HIF-1 o: - hypoxia-inducible factor-1 
HR = homologous recombination 
HR32B = human homologue of the yeast RAD23 protein 
HUVECs = human umbilical vein endothelial cells 
IL-2 = interleukin 2 
LP-BER - long-patch base-excision repair 
MeSeH = meth y lselenol 
MGMT = C/'-methylguanine-DNA methyltransferase 
MiTF = microphthalmia-associated transcription factor 
MLHl = MutL ho1nologue 1 
MMR = misn1atch repair 
MMS = methyl methane sulfonate 
MPG = N-methylpurine DNA glycosylase 
MRN = Mrell/Rad50/ Nbsl 
MSH2 = MutS homologue 2 
MSH3 = MutS homologue 3 
MSH6 = MutS homologue 6 
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MYH = MutY homologue 
NAC = N-acetyl-L-cysteine 
NEIL = fgp/nei family DNA glycosylase 
NER = nucleotide-excision repair 
NF-KB = nuclear factor kappa B 
NHEJ = nonhon1ologous end joining 
NK = natural killer 
NTH = ho1nologue of Escherichia coli endonuclease 
III (nth) 
06-meG =Cl' m.ethyl guanine 
P2Y = purinergic receptor 
PCNA = proliferating cell nuclear antigen . 
PMSl = postmeiotic-segregation increased-1 prote~ 
PMS2 = postmeiotic-segregation increased-2 protein 
Pol f3 = DNA polymerase /3 
PRX = peroxiredoxin 
PTEN = phosphatase and tensin homologue deleted 
on chromosome 10 
Ref-1 = redox effector factor 1 
RFC = replication factor C 
RNA Pol ll = RNA polymerase II 
ROS = reactive oxygen species 
RPA = replication protein A 
SeMet = selenomethionine 
siRNA = small interfering RNA 
SMUGl = mamn1alian 5-formyluraci.l DNA glycosylase 
SP-BER = short-patch base-excision repair 
ssDNA = single-strand DNA 
TCR = transcription-coupled repair 
TDG = thy1ni.ne-DNA glycosylase 
TFIIH = transcription factor IIH 
TR = thioredoxin reductase 
TRX = thioredoxin 
TSH = thyroid-stimulating hormone 
UNG = uracil-DNA glycosylase 
WRN = Werner protein, deficient in Werner syndrome 
XPB = xeroderma pigmentosum complementary 
group B protein 
XPC = xeroderma pign1entosum complementary 
group C protein 
XPD = xeroderma pigmentosurn complementary 
group D protein . . . 
XRCCl = x-ray repair complementing defective repair 1n 
Chinese hamster cells 1 
XRCC4 = x-ray repair complementing defective repair in 
Chinese hamster cells 4 
